RegMed Forum: Process Development and Translation of ATMP projects
Advanced Therapy Medicinal Products (ATMPs) represent a novel class of therapeutics which are in the process of revolutionizing therapeutic options in cancer, immunopathologies, genetic diseases and beyond. Currently, Europe and Germany lack behind in performing especially early phase clinical trials in the field.
The aim of this event is to discuss key aspects in process development and manufacturing of ATMPs as well as their translation into the clinics together with representatives from academic research, contract manufacturing organizations, spin-offs and big pharma companies.
We will examine the following topics and issues, among others:
- Challenges in manufacturing
- Requirements in the development process
- Contribution of academic research to overcoming GMP bottlenecks
- Interest of companies in academic development
What to expect?
- Talks & panel discussions with different stakeholders.
- Focussed breakout sessions on specific topics.
- Onsite networking opportunity
- Industry exhibition to present your products and services
Confirmed speakers (as of Nov 2024):
- Michael Apel - Miltenyi GmbH
- Garima Bhardwaj - Berlin Institute of Health
- Christoph Conrad - Berlin Institute of Health
- Halvard Bönig - Goethe University Frankfurt am Main & German Red Cros
- Paul Franz, Fraunhofer Institute for Cell Therapy and Immunology
- Martin Hildebrandt - TU Munich
- Christian Ebel - Tetec GmbH
- Daniel Forler - Bayer AG
- Annette Künkele-Langer - Charité Universitätsmedizin Berlin & BeCAT
- Elke Luger - GCT Germany
- Petra Reinke - BCRT & BeCAT
- Guilietta Roel - co.don AG
- Verena Schöwel-Wolf - MyoPax GmbH
- Sven Stegemann - DWI Leibniz Institut for Interactive Materials Aachen
- Wolfram Hubertus Zimmermann - University Medical Center Göttingen
HERE you find the agenda.
You should attend if you:
- Develop or manufacture ATMPs
- Provide services or products that support the field of ATMP development, manufacturing and translation
- Want to learn about pros and cons for development and manufacturing of ATMPs in an academic vs. industrial setting
- Expand your knowledge about clinical trials with ATMP and learn from start ups about challenges during translation of ATMP projects
- Explore new partnership opportunities for your institution
- Wish to expand your network
Who will be attending?
Academic researchers, contract manufacturers and spin-offs/start-ups interested in process development and translation of ATMP projects.
Participation is free of charge.
The RegMed Forum 2025 is organized in collaboration with the BIH Center for Regenerative Therapies (BCRT), the HealthCapital Berlin-Brandenburg cluster, Berlin Partner, the German Stem Cell Network e.V. (GSCN) and the National Network Office GCT Germany.
About the event series
The BIH Center for Regenerative Therapies (BCRT), Charité – Universitätsmedizin Berlin and the Cluster Health Capital Berlin-Brandenburg are jointly organizing the international RegMed Forum since 2014.
This event series provides the opportunity to hear and discuss science in the field of regenerative medicine - from basic research to clinical implementation and industrialization. In addition to a comprehensive scientific program there will be opportunities to network and discuss with industry and research groups in the regenerative medicine field.
About the BIH Center for Regenerative Therapies (BCRT)
The research landscape of Berlin-Brandenburg has developed into one of the most important international clusters for regenerative medicine. A major contribution to this development has been the BCRT - an interdisciplinary clinical translational center operated by the Berlin Institute of Health at Charité (BIH).
The primary focus of the BCRT is the development of novel methods to promote endogenous regeneration to address acute and chronic diseases of the immune, musculoskeletal and cardiovascular systems. This includes using cells, biomaterials and biological factors or a combination thereof to provide long-term and possibly curative treatments. With respect to the development and implementation of innovative therapies and products from the BCRT, the first potential success story for a novel regenerative product is starting to emerge. Virus-specific T-cell products for long-term protection against serious infections are being evaluated in onsite clinical studies for treatment of patients with a weakened immune system. Following the concept of refined translation, i.e. iterative incorporation of (pre-)clinical research findings into product development, and the use of biomarkers, the BCRT is actively pushing further treatment concepts towards clinical evaluation. This also includes new cell-based therapies for heart disease and muscle injuries.
About the Cluster Health Capital
The German capital region is one of the world's leading locations for the healthcare industry, healthcare, and the life sciences. Leading global companies, renowned scientists, first-class hospitals, innovative start-ups, and specialists from all over the world work together in Berlin-Brandenburg each day to deliver the very best goods and services for the regional and global healthcare markets.
The cluster management team at Berlin Partner for Business and Technology and Brandenburg Economic Development Corporation (WFBB) drives networking and the technology transfer in the region and supports international companies interested in relocating to the German capital region.
We are looking forward to meeting you on February 27, 2025 in Berlin!
